SEC Form D private-offering filing
Thiogenesis Therapeutics, Corp.
A new SEC Form D private-offering notice from Toronto, ON, Canada, a $28,964 filer-stated offering target in Biotech. The source filing is one click away.
Thiogenesis Therapeutics is a clinical-stage biotech developing sulfur-based thiol therapies, including lead candidate TTI-0102, to treat mitochondrial diseases such as MELAS and Leigh syndrome; it trades as TSXV: TTI and OTCQX: TTIPF.
Filed 2026-06-09Filed to raise $28,964First money in 2026-06-01Raised so far $28,964HQ (as filed) Toronto, ON, CanadaSector Biotech ✓Stage (inferred) Pre-seedCall status Non-US principal office
Source linked the Form D on EDGAR↗Website verified thiogenesis.com↗Named in the filing 5 executives & directors
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.